Peripheral T Cell Lymphoma Clinical Trial
Official title:
Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma: A Phase II Clinical Trial
The purpose of this study is to evaluate the efficacy and safety of Chidamide with ICE regimen in patients with relapsed/refractory Peripheral T Cell lymphoma.
Efficacy of the combined regimen is evaluated primarily by objective remission rate,
including complete remission, unverified complete remission and partial remission, also by
duration of remission, progression free survival, and overall survival.
Safety is accessed by:
1. The type, incidence, severity of incidents related to the use of the regimen.
2. Laboratory abnormalities, including the type, incidence, severity, relationship with
the use of the regimen.
3. Incidence of level 3-4 incidents and laboratory abnormalities.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04526834 -
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05559008 -
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06083701 -
Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04083495 -
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT05979792 -
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
|
Early Phase 1 | |
| Recruiting |
NCT04984837 -
Study of Lacutamab in Peripheral T-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT06072131 -
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
|
Phase 3 | |
| Completed |
NCT01716806 -
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
|
Phase 2 | |
| Terminated |
NCT03947255 -
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04028440 -
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
|
Early Phase 1 | |
| Not yet recruiting |
NCT05923502 -
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
|
||
| Recruiting |
NCT05883449 -
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
|
Phase 2 | |
| Recruiting |
NCT05377827 -
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03586999 -
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04489264 -
The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
|
||
| Recruiting |
NCT06151106 -
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT02753543 -
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT06089941 -
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
|
||
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|